Beam Therapeutics, Inc.

Traded on the St. Petersburg Stock Exchange
Beam Therapeutics Inc. operates as a biotechnology company. The Company develops DNA base editing technologies for the treatment of human diseases.
Beam Therapeutics, Inc. stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Beam Therapeutics, Inc. balance sheet

Report period2019 2020 2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Beam Therapeutics, Inc. cash flows

Report period2019 2020 2021 2022 2023 Q2 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Beam Therapeutics, Inc. multipliers

Report period2019 2020 2021 2022 2023 Q2 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Beam Therapeutics, Inc. profitability

Report period2019 2020 2021 2022 2023 Q2 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Beam Therapeutics, Inc. assets
Beam Therapeutics, Inc. cash flows

Beam Therapeutics, Inc. shares

TickerNameTypeNominal valueISINPrice
BEAM:USBeam TherapeuticsCommon share-US07373V1052$23.9
Beam Therapeutics, Inc. news
09.05.2022
Beam Therapeutics' GAAP loss for 3 months of 2022 was $69.214 million, down 2.9 times from $201.56 million in the previous year. Revenue increased multiple times to $8.432 million from $0.006 million a year earlier.
Source: {source} pictogram investors.beamtx.com
Pictogram next
28.02.2022
Beam Therapeutics' GAAP loss for 2021 was $370.638 million, up 90.5% from $194.592 million the previous year. Revenue increased multiple times to $51.844 million from $0.024 million a year earlier.
Source: {source} pictogram investors.beamtx.com
Pictogram next
10.01.2022
Beam Therapeutics has entered into a collaboration agreement with Pfizer to advance new in vivo genome base editing programs for rare genetic diseases of the liver, muscle and central nervous system. Beam will conduct all research activities, and Pfizer will be able to select exclusive worldwide licenses for each of the three candidate candidates at a total...
Source: {source} pictogram investors.pfizer.com
Pictogram next
08.11.2021
Beam Therapeutics' GAAP loss for 9M 2021 was $305.931 million, up 3.1 times from $99.128 million in the previous year. Revenue increased multiple times to $775 million from $18 million a year earlier.
Source: {source} pictogram investors.beamtx.com
Pictogram next
All Beam Therapeutics, Inc. news
General information
Company nameBeam Therapeutics, Inc.
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address510 LAKE COOK ROAD DEERFIELD IL 60015 8479488888
Mailing address510 LAKE COOK ROAD DEERFIELD IL 60015
Websitewww.beamtx.com
Information disclosurewww.sec.gov